• Supply chain strategy: Following a US FDA warning letter to supplier Pharmathen, Cipla is pursuing facility remediation alongside establishing alternate manufacturing with a US-based contract partner to bring its complex product back to market.
• Generic Advair outlook: After previous delays linked to the Indore facility and a subsequent tech transfer to the US, Cipla expects US FDA approval for generic Advair soon or in the coming quarter.
• US revenue guidance: The company is targeting a $1 billion US sales run rate by FY28, which management expects to establish a new base for future growth despite the loss of Revlimid exclusivity.
• Pipeline growth drivers: The $1 billion target is backed by complex respiratory assets—including the approved Ventolin, alongside Advair and Symbicort—as well as peptide products and approved drugs like Liraglutide, DAPA, and Nintedanib.